Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem

Onkourologiâ

B. Ya. Alekseev¹ 

[1] N.А. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;

关键词: prostate cancer;    chemotherapy;    androgen deprivation therapy;    castration resistance;    docetaxel;    cabazitaxel;    abiraterone;    enzalutamide;   

DOI  :  10.17650/1726-9776-2015-11-3-108-116

来源: DOAJ

【 摘 要 】

The paper reviews the current possibilities of cytostatic chemotherapy in patients with metastatic prostate cancer. It gives the data of studies dealing with the early use of docetaxel in patents with hormone-susceptible tumors and analyzes approaches to sequential therapy with docetaxel, cabazitaxel, and antiandrogens (abiraterone, enzalutamide) in patients with castration-refractory prostate cancer. Assessment of the prognostic role of different clinical and biological factors could provide an algorithm for the choice of first- and second-line therapy in patients with castration resistance.

【 授权许可】

Unknown